Company Recursion Pharmaceuticals, Inc.

Equities

RXRX

US75629V1044

Biotechnology & Medical Research

Market Closed - Nasdaq 21:00:00 17/07/2024 BST 5-day change 1st Jan Change
8.35 USD -2.91% Intraday chart for Recursion Pharmaceuticals, Inc. +15.49% -15.31%

Business Summary

Recursion Pharmaceuticals, Inc. is a clinical-stage TechBio company decoding biology to industrialize drug discovery. Its Recursion Operating System (OS), a platform built across diverse technologies, enables the Company to map and navigate trillions of biological and chemical relationships within the Recursion Data Universe. The Company integrates physical and digital components as iterative loops of atoms and bits scaling wet lab biology and chemistry data organized into virtuous cycles with computational tools to rapidly translate in silico hypotheses into validated insights and novel chemistry. Its clinical programs include REC-994, REC-2282, REC-4881 and REC-3964. REC-994 is an orally bioavailable, superoxide scavenger small molecule being development for the treatment of symptomatic cerebral cavernous malformation (CCM). REC-2282 for the potential treatment of neurofibromatosis type 2. REC-3964 for the prevention of recurrent Clostridioides difficile infection.

Number of employees: 500

Sales per Business

USD in Million2022Weight2023Weight Delta
Drug Discovery
100.0 %
40 100.0 % 45 100.0 % +11.88%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
100.0 %
40 100.0 % 45 100.0 % +11.88%

Managers

Managers TitleAgeSince
Founder 41 04/11/13
Founder 42 04/11/13
Founder 62 04/11/13
President 49 30/06/18
Director of Finance/CFO 41 29/02/20
Chief Tech/Sci/R&D Officer - -
Chief Tech/Sci/R&D Officer - 15/08/21
Chief Tech/Sci/R&D Officer 41 28/02/17
Chief Tech/Sci/R&D Officer - -
Chief Tech/Sci/R&D Officer 59 31/05/23

Members of the board

Members of the board TitleAgeSince
Chairman 61 19/03/20
Founder 62 04/11/13
Founder 42 04/11/13
Director/Board Member 48 31/07/18
Director/Board Member 35 31/08/16
Founder 41 04/11/13
Director/Board Member 47 31/03/20

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 10 7,389,871 0 0 92.91 %
Stock B 1 265,427,675 253,461,619 ( 95.49 %) 0

Shareholders

NameEquities%Valuation
ARK Investment Management LLC
9.429 %
24,587,561 9.429 % 184 M $
Baillie Gifford & Co.
9.230 %
24,067,804 9.230 % 181 M $
Vanguard Fiduciary Trust Co.
6.142 %
16,014,764 6.142 % 120 M $
RA Capital Management LP
5.900 %
15,384,615 5.900 % 115 M $
Mubadala Investment Co. (Investment Company)
4.980 %
12,985,927 4.980 % 97 M $
Kinnevik AB (Investment Company)
4.566 %
11,905,668 4.566 % 89 M $
BlackRock Advisors LLC
4.276 %
11,150,169 4.276 % 84 M $
Nikko Asset Management Americas, Inc.
3.974 %
10,362,803 3.974 % 78 M $
10,352,356 3.970 % 78 M $
DCVC Management Co. LLC
3.794 %
9,892,261 3.794 % 74 M $
NameEquities%Valuation
7,168,575 75.71 % 54 M $

Company contact information

Recursion Pharmaceuticals, Inc.

41 South Rio Grande Street

84101, Salt Lake City

+

http://www.recursion.com
address Recursion Pharmaceuticals, Inc.(RXRX)
  1. Stock Market
  2. Equities
  3. RXRX Stock
  4. Company Recursion Pharmaceuticals, Inc.